These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25655830)

  • 1. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
    Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
    Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
    Yu H; Tweedie D
    Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
    Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Hara Y; Okuda T; Moriwaki T
    Xenobiotica; 2012 Feb; 42(2):127-38. PubMed ID: 22117526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
    Sudsakorn S; Bahadduri P; Fretland J; Lu C
    Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
    Evers R; Dallas S; Dickmann LJ; Fahmi OA; Kenny JR; Kraynov E; Nguyen T; Patel AH; Slatter JG; Zhang L
    Drug Metab Dispos; 2013 Sep; 41(9):1598-609. PubMed ID: 23792813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Science Is Driving Regulatory Guidances.
    Yang X; Fan J; Zhang L
    Methods Mol Biol; 2021; 2342():595-629. PubMed ID: 34272707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.
    Sane RS; Ramsden D; Sabo JP; Cooper C; Rowland L; Ting N; Whitcher-Johnstone A; Tweedie DJ
    Drug Metab Dispos; 2016 Mar; 44(3):466-75. PubMed ID: 26684498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
    Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
    Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018.
    Steinbronn C; Yang X; Yu J; Dimova H; Huang SM; Ragueneau-Majlessi I; Isoherranen N
    Clin Pharmacol Ther; 2021 Aug; 110(2):452-463. PubMed ID: 33835478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
    Riley RJ; Wilson CE
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.
    Yeung CK; Fujioka Y; Hachad H; Levy RH; Isoherranen N
    Clin Pharmacol Ther; 2011 Jan; 89(1):105-13. PubMed ID: 21124313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
    Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
    Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.
    Isoherranen N; Hachad H; Yeung CK; Levy RH
    Chem Res Toxicol; 2009 Feb; 22(2):294-8. PubMed ID: 19216580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity.
    Crouch RD; Morrison RD; Byers FW; Lindsley CW; Emmitte KA; Daniels JS
    Drug Metab Dispos; 2016 Aug; 44(8):1296-303. PubMed ID: 26936972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the transport properties of metabolites: case studies and considerations for drug development.
    Zamek-Gliszczynski MJ; Chu X; Polli JW; Paine MF; Galetin A
    Drug Metab Dispos; 2014 Apr; 42(4):650-64. PubMed ID: 24346835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.